FOR vs REGN · P/E 8.7, rev $1.66B vs P/E 14, rev $14.34B
Forestar Group Inc (FOR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Forestar Group Inc (FOR) is a real estate - development company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported FOR revenue for 2025-09-30 was $1.66B. Net income was $167.9M. Revenue was up 10.1% from 2024-09-30 to 2025-09-30. FOR currently screens at market cap $1.45B and trailing P/E 8.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FOR currently screens at market cap $1.45B and trailing P/E 8.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FOR and REGN stock pages for the full models.
Not investment advice.